

Brent A Appleton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7725050/publications.pdf>

Version: 2024-02-01

30
papers

2,629
citations

279798

23
h-index

454955

30
g-index

30
all docs

30
docs citations

30
times ranked

3957
citing authors

#	ARTICLE	IF	CITATIONS
1	Design and Discovery of <i>N</i> -(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 2013-2027.	6.4	27
2	Fragment-Based Drug Discovery of Inhibitors of Phosphopantetheine Adenylyltransferase from Gram-Negative Bacteria. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 3309-3324.	6.4	24
3	Discovery and Optimization of Phosphopantetheine Adenylyltransferase Inhibitors with Gram-Negative Antibacterial Activity. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 3325-3349.	6.4	26
4	Design and synthesis of potent RSK inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 3197-3201.	2.2	10
5	Mathematical and Structural Characterization of Strong Nonadditive Structure-Activity Relationship Caused by Protein Conformational Changes. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7754-7766.	6.4	10
6	Design and Discovery of <i>N</i> -(2-Methyl-5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4869-4881.	6.4	37
7	Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 5221-5224.	2.2	8
8	Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug Design. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 3034-3045.	6.4	20
9	Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 961-965.	2.8	37
10	Discovery of Potent and Selective RSK Inhibitors as Biological Probes. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6766-6783.	6.4	50
11	Novel Potent and Selective Inhibitors of p90 Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven Cancers. <i>Molecular Cancer Research</i> , 2014, 12, 803-812.	3.4	60
12	Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 5704-5709.	2.2	14
13	2-Amino-7-substituted benzoxazole analogs as potent RSK2 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 1592-1596.	2.2	21
14	A Structural Portrait of the PDZ Domain Family. <i>Journal of Molecular Biology</i> , 2014, 426, 3509-3519.	4.2	71
15	A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients. <i>Cancer Research</i> , 2011, 71, 5255-5264.	0.9	109
16	Structure of IL-33 and Its Interaction with the ST2 and IL-1RAcP Receptors: Insight into Heterotrimeric IL-1 Signaling Complexes. <i>Structure</i> , 2009, 17, 1398-1410.	3.3	174
17	Inhibition of Wnt signaling by Dishevelled PDZ peptides. <i>Nature Chemical Biology</i> , 2009, 5, 217-219.	8.0	143
18	Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site. <i>Science</i> , 2009, 323, 1610-1614.	12.6	342

#	ARTICLE	IF	CITATIONS
19	Comprehensive Analysis of the Factors Contributing to the Stability and Solubility of Autonomous Human VH Domains. <i>Journal of Biological Chemistry</i> , 2008, 283, 3639-3654.	3.4	157
20	A Specificity Map for the PDZ Domain Family. <i>PLoS Biology</i> , 2008, 6, e239.	5.6	410
21	Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding. <i>EMBO Journal</i> , 2007, 26, 4902-4912.	7.8	192
22	Structural and functional analysis of the ligand specificity of the HtrA2/Omi PDZ domain. <i>Protein Science</i> , 2007, 16, 1738-1750.	7.6	51
23	Structural and functional analysis of the PDZ domains of human HtrA1 and HtrA3. <i>Protein Science</i> , 2007, 16, 2454-2471.	7.6	86
24	The Crystal Structure of Murine Coronin-1: A Regulator of Actin Cytoskeletal Dynamics in Lymphocytes. <i>Structure</i> , 2006, 14, 87-96.	3.3	106
25	Comparative Structural Analysis of the Erbin PDZ Domain and the First PDZ Domain of ZO-1. <i>Journal of Biological Chemistry</i> , 2006, 281, 22312-22320.	3.4	70
26	Convergent and Divergent Ligand Specificity among PDZ Domains of the LAP and Zonula Occludens (ZO) Families. <i>Journal of Biological Chemistry</i> , 2006, 281, 22299-22311.	3.4	94
27	Crystal Structure of the Cytomegalovirus DNA Polymerase Subunit UL44 in Complex with the C Terminus from the Catalytic Subunit. <i>Journal of Biological Chemistry</i> , 2006, 281, 5224-5232.	3.4	56
28	Residues of Human Cytomegalovirus DNA Polymerase Catalytic Subunit UL54 That Are Necessary and Sufficient for Interaction with the Accessory Protein UL44. <i>Journal of Virology</i> , 2004, 78, 158-167.	3.4	70
29	Specific Residues in the Connector Loop of the Human Cytomegalovirus DNA Polymerase Accessory Protein UL44 Are Crucial for Interaction with the UL54 Catalytic Subunit. <i>Journal of Virology</i> , 2004, 78, 9084-9092.	3.4	58
30	The Cytomegalovirus DNA Polymerase Subunit UL44 Forms a C Clamp-Shaped Dimer. <i>Molecular Cell</i> , 2004, 15, 233-244.	9.7	96